Sarah Beck

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 711 citations · Full text

Medicine, Oncology, Pharmacology +17

AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

Paul R. Gavine, Lorraine Mooney, Elaine Kilgour et al. · Cancer Research · 2012 · 499 citations

Medicine, Oncology, Pharmacology +16

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

D. Mark Hickinson, Teresa Klinowska, Georgina Speake et al. · Clinical Cancer Research · 2010 · 120 citations

Medicine, Oncology, Pharmacology +17

The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction

Judith M.M. van Eeuwijk, David Stegner, David Lamb et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2016 · 81 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

TMEM16F-Mediated Platelet Membrane Phospholipid Scrambling Is Critical for Hemostasis and Thrombosis but not Thromboinflammation in Mice—Brief Report

Ayesha Baig, Elizabeth J. Haining, Sarah Beck et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2016 · 71 citations · Full text

Medicine, Molecular Biology, Neuroscience +17